Top Story Today
Xenon's Epilepsy Drug Just Delivered Results So Good That Analysts Are Tripping Over Each Other
Xenon Pharmaceuticals' azetukalner posted a 42.7 percentage-point placebo-adjusted seizure reduction in its Phase 3 trial, nearly doubling Wall Street's consensus estimate of 25-30%. The stock surged roughly 50% in a single session. At the higher dose, over half of treatment-resistant patients achieved at least a 50% reduction in seizures. Jefferies slapped a $100 price target on the stock. Xenon plans to file with the FDA in Q3 2026, and if approved, azetukalner would be the first Kv7 potassium channel opener ever greenlit for epilepsy.
Why it matters: For the roughly 30% of epilepsy patients who don't respond to existing drugs, this represents a genuinely new mechanism of action. With analysts projecting peak sales above $2 billion, the dataset validates Xenon's ion channel platform and could reshape the epilepsy treatment landscape.
Read more →Clinical Moves
Pfizer Built a Three-Headed Antibody to Come for Dupixent's Throne
A first-in-class trispecific antibody from Pfizer, tilrekimig, hit Dupixent-level efficacy in a Phase 2 eczema trial by blocking three inflammatory targets (IL-4, IL-13, and TSLP) with a single molecule. The middle dose delivered 51.9% of patients reaching EASI-75, with fewer eye side effects than the reigning champ. Phase 3 is planned for 2026, with expansion into asthma and COPD on the horizon.
Read more →Gilead Broke Up with Assembly Bio's Hepatitis B Drug, Kept the Herpes Programs
Gilead declined its option on Assembly Biosciences' HBV antiviral ABI-4334 while keeping the herpes programs from the same partnership. The timing is telling: GSK's bepirovirsen just nailed two Phase 3 trials for a potential functional cure, raising the bar for every early-stage HBV asset. Assembly is now searching for a new partner.
Read more →Deals and M&A
Novartis Dropped $2 Billion on a Breast Cancer Drug with No Clinical Data
Novartis acquired Pikavation Therapeutics for $2 billion upfront (plus $1 billion in milestones) to get SNV4818, a mutant-selective PI3K-alpha inhibitor still in Phase 1/2. The urgency: Eli Lilly paid $2.5 billion for a competing asset in January 2025. Novartis needs this drug to pair with its blockbuster Kisqali and replace the aging Piqray. Trial results won't arrive until 2027.
Read more →GSK Sold a Drug Days Before the FDA Approved It (on Purpose)
GSK licensed linerixibat to Alfasigma for up to $690 million, then the FDA approved it days later as Lynavoy, the first treatment specifically for PBC-related itch. GSK pocketed $300 million upfront and kept royalties, while refocusing on bigger liver disease targets. Alfasigma gets a first-in-class orphan drug and a global regulatory pipeline with decisions pending in Europe, UK, and China.
Read more →A $328 Million Bet on Epilepsy's Most Precise Drug Yet
Tenacia Biotechnology licensed Greater China rights to Rapport Therapeutics' RAP-219 for $20 million upfront and up to $328 million total. The drug targets TARPy8, a protein concentrated in seizure-prone brain regions, aiming to stop seizures without the dizziness and sedation of current treatments. Phase 3 kicks off in Q2 2026, with Tenacia adding Chinese trial sites to accelerate enrollment.
Read more →